{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
niacin
to a specific field?
There is no information about biological or medical application of ferrous nicotinate (also known as iron dinicotinate)
Status:
US Previously Marketed
Source:
ISOPAQUE 280 by GE HEALTHCARE
(1974)
Source URL:
First approved in 1974
Source:
ISOPAQUE 280 by GE HEALTHCARE
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Meglumine (N-methyl-D-glucamine) is a poorly metabolized derivative of sorbitol that has regulatory acceptance as a benign excipient for drug formulation to increase aqueous solubility of lipophilic drugs and improve their absorption. In conjugated form meglumine is used as a contrast agent.
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
Omega-3 Support by TMIG, Inc.
(2015)
Source URL:
First approved in 1961
Source:
ADELGADINA by ProMex LLC
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Nicotinyl methylamide (N-methylnicotinamide) is an experimental drug with no approved indication or marketed formulation. Nicotinyl methylamide is a metabolite of niacin (or nicotinamide) and is commonly found in human urine. However low levels of urinary excretion of N-methylnicotinamide indicates niacin deficiency. In patients with liver cirrhosis nicotinamide methylation is increased leading to a rise in urinary N-methylnicotinamide. The hyperfunction of this methylating pathway might play a protective role against the toxic effect of intracellular accumulation of nicotinamide deriving from the catabolic state of cirrhosis. N-methylnicotinamide is known to inhibit choline transport and reduce choline clearance out of the brain. N-methylnicotinamide has been found to be a microbial metabolite. N-methylnicotinamide inhibits arterial thrombosis in hypertensive rats. N-methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. The antithrombotic effect of N-methylnicotinamide is accompanied by platelet inhibition and enhanced fibrinolysis, due to the decrease production of plasminogen activator inhibitor -1.
Status:
Possibly Marketed Outside US
Source:
Teonicon by Bracco [Italy]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
There are a few information in the literature about pimephylline nicotinate. The metabolites of this compound were determined in the rats.
Status:
Possibly Marketed Outside US
Source:
Cholexamin by Kyorin Pharmaceutical
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Hypolipidemic agent, Nicomol is an ingredient of Cholexamin in Japan. Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched by KYORIN Pharmaceutical in 1971. It is indicated for the treatment of hyperlipemia, improvement in peripheral circulatory disorder resulting from the following diseases Chilblain, limb arterial occlusive disease (obstructive thromboarteritis and arteriosclerosis obliterans), Raynaud syndrome.
Status:
Possibly Marketed Outside US
Source:
Pemix by Prodes [Spain]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Pirozadil (Pemix), a hypolipidemic agent that improves cerebral blood flow and Inhibits platelet aggregation. This drug was studied for the treatment of patients with Type IIa hyperlipoproteinemia.
